nature medicine semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial Considering a Weight Loss Drug?

Pregnancy and breastfeeding - GLP-1 medications are not recommended during pregnancy or breastfeeding

products often lack quality control, raising fears of contamination, incorrect dosing, or dangerous ingredients, with the FDA warning against compounding it due to insufficient safety data

Apr 6 2015;177(15)

Since the medication causes glucose-dependent insulin release and did not cause hypoglycemia but suppressed appetite, liraglutide and semaglutide were both approved for weight loss in patients without diabetes [33, 34]

Additionally, oxidative stress, lipid peroxidation, and iron homeostasis imbalance exacerbate the aggregation of Htt with other proteins, leading to increased glutamate excitotoxicity, disrupted mitochondrial function, altered autophagy mechanisms, impaired axonal transport, and ultimately neuronal degeneration, thereby causing the motor, cognitive, and behavioral symptoms of HD (Reichert et al., 2020)